What are the main indications for Osimertinib?

Osimertinib is an oral anticancer drug used to treat certain types of lung cancer.

Osimertinib is mainly suitable for the treatment of non-small cell lung cancer (NSCLC), especially for patients with epidermal growth factor receptor (EGFR) gene-sensitive mutations. Specifically, its indications include:

1.Patients with epidermal growth factor receptor(EGFR)exon 19 deletion or Adult patients with Exon 21L858R mutations are treated with adjuvant therapy for non-small cell lung cancer(non-small cell lung cancer) after tumor resection. 2.First-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have EGFRexon19 deletion or exon21 L858R mutation.

3.With combined pemetrexed and platinum-based chemotherapy tuberculosis, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFRexon19deletion or exon21 L858Rmutation, as detected by FDAapproved tests.

4.A FDA-approved trial testing the treatment of adult patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer whose disease is EGFRtyrosine kinase inhibitors(TKI)Progress during or after treatment.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor with remarkable therapeutic effect. In clinical trials, osimertinib showed high efficacy against EGFR sensitive mutations and T790M resistant mutations. For some patients, sequential treatment with osimertinib or other drugs can effectively control tumors and prolong survival, which may even reach 4-5 years or more. However, although osimertinib is highly effective and has relatively few side effects, long-term use may cause certain drug resistance problems.